Balversa

Prior Authorization Request

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-866-249-6155**. If you have questions regarding the prior authorization, please contact CVS Caremark at **1-866-814-5506.** For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do_not_call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name: _____ **Date**: _____
Patient's ID: _____ **Patient's Date of Birth:** _____
Physician's Name: _____
Specialty: _____ **NPI#:** _____
Physician Office Telephone: _____ **Physician Office Fax:** _____
Request Initiated For: _____

1. What is the diagnosis?
   ❑ Urothelial carcinoma
   ❑ Other _____
2. What is the ICD-10 code? _____
3. Does the patient have locally advanced or metastatic disease?
   ❑ Yes - locally advanced ❑ Yes - metastatic ❑ No
4. Is the patient currently receiving treatment with Balversa? ❑ Yes ❑ No *If No, skip to #6*
5. Has the patient experienced disease progression or an unacceptable toxicity from treatment with Balversa?
   ❑ Yes - disease progression ❑ Yes - unacceptable toxicity ❑ No *No further questions*
6. Has the patient been tested for fibroblast growth factor receptor (FGFR)3 and FGFR2 genetic alterations?
   ACTION REQUIRED: If Yes, attach laboratory test results. ❑ Yes ❑ No ❑ Unknown
7. Does the patient have a susceptible fibroblast growth factor receptor (FGFR)3 or FGFR2 genetic alteration?
   ❑ Yes ❑ No
8. Has the patient's disease progressed during or following at least one line of prior platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy?
   ❑ Yes ❑ No

I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by CVS Caremark or the benefit plan sponsor.

X_____
Prescriber or Authorized Signature **Date (mm/dd/yy)**

Send completed form to: Case Review Unit, CVS Caremark Prior Authorization Fax: 1-866-249-6155